Hossein Taghizadeh, MD-PhD from the Medical University of Vienna; University Hospital of St. Poelten speaks about MAP 2021 Abstract – 20P – Tissue agnostic application of mTOR inhibitors for the management of therapy refractory solid tumors.
Link to Abstract:
https://cslide.ctimeetingtech.com/map2021_virtual/attendee/confcal_1/presentation
Background:
Based on the particular molecular profiles of extensively pretreated cancer patients following failure of all traditional treatments, we investigated the efficacy, feasibility, and limitations of using mTOR inhibitors.
Methods:
We looked at the genetic characteristics of 70 cancer patients in this single-center, real-world retrospective analysis of our precision medicine platform. Next-generation sequencing panels of mutation hotspots, MSI testing, and immunohistochemistry were used to examine tumor tissues from the patients. After a consensus discussion, a multidisciplinary panel analyzed all of the profiles to make a tailored therapy suggestion.
Results:
Seventy cancer patients with p-mTOR pathway activity were given mTOR inhibitor-based targeted therapy, and 17 (24 percent) of them subsequently received it. Four patients (6%) had their disease stabilized. The disease progressed in the remaining 13 cases (19%). Treatment failure occurred after a median of 3.2 months. We found 133 mutations in 60 cases in total. TP53, PTEN, KRAS, ATR, and POLE were the five most common mutations, accounting for almost 40% (46%) of all alterations.
Conclusions:
In therapy-refractory solid tumors, the antitumoral activity of mTOR inhibitor was limited.